Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

How a commonly “silent disease” is driving urgency and novelty in the liver disease treatment paradigm and what can we hope for.

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.

Utilizing a filamentous fungus in the gut microbiome may provide a new strategy for treating metabolic dysfunction-associated ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo.